Investigational drug · Phase 2
HB-202
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HPV-Related Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "HB-202"
First trial start
2019
Dec 11, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB-202", any sponsor or status.
Conditions studied
As listed on its trial records.
- HPV-Related Squamous Cell Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HB-202" as an intervention, largest first.
Hookipa Biotech GmbHIndustry
NCT04180215 · 198 participants · Start Dec 11, 2019 · Primary completion Jan 9, 2025
Drug: HB-201 intravenous administration.; HB-202 intravenous administration alternating with HB-201 intravenous administration. and 4 more · For: HPV-Related Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Fayetteville, Arkansas · 34 sites in all
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck CancersActive, not recruiting
University of ChicagoAcademic, hospital or other
NCT05108870 · 35 participants · Start Aug 22, 2022 · Primary completion Jan 1, 2027
Drug: HB-201; HB-202 and 2 more · For: Human Papilloma Virus; HPV; HPV Positive Oropharyngeal Squamous Cell Carcinoma and 1 more
Sites: Chicago, Illinois
- A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)Active, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06373380 · 7 participants · Start Apr 15, 2024 · Primary completion Apr 2027
Drug: HB-200 · For: HPV16+ Squamous Cell Carcinoma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal CancerPivotal-lookingWithdrawn
Hookipa Biotech GmbHIndustry
NCT06513884 · 0 participants · Start Dec 2024 · Primary completion Nov 2029
Drug: HB-202/HB-201 alternating 2-vector therapy; Placebo and 1 more · For: Oropharyngeal Squamous Cell Carcinoma Recurrent
Newest research
PubMed records naming it or its code names, newest first.
- Innate immune activation profiles are associated with polarization of the T cell response to recombinant arenaviral vectors.
Szaffich S, Just V, Cvetkovic N, et al. · Front Syst Biol 2026
- Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.
Lauterbach H, Schmidt S, Katchar K, et al. · Front Oncol 2021
Also in development for HPV-Related Squamous Cell Carcinoma
- HB-201HB-202 alternating using CD8 PET Tracer, Zr-Df-IAB22M2CPhase 21 trial
Hookipa Biotech GmbH · HPV-Related Squamous Cell Carcinoma
- SCG142Phase 21 trial
SCG Cell Therapy Pte. Ltd. · HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.